£2.5M
The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
